About Jasper

Jasper is a clinical-stage biotechnology company developing briquilimab, a monoclonal antibody targeting c-Kit (CD117) as a therapeutic for chronic mast and stem cell diseases such as chronic urticaria and lower to intermediate risk myelodysplastic syndromes (MDS) and as a conditioning agent for stem cell transplants for rare diseases such as sickle cell disease (SCD), Fanconi anemia (FA) and severe combined immunodeficiency (SCID). To date, briquilimab has a demonstrated efficacy and safety profile in over 145 dosed subjects and healthy volunteers, with clinical outcomes as a conditioning agent in SCID, acute myeloid leukemia (AML), MDS, FA, and SCD.

Our History

Jasper Therapeutics was founded by Dr. Judith Shizuru, a Stanford professor, and Dr. Susan Prohaska, a Stanford-trained immunology /stem cell scientist and drug developer, with the goal of targeting c-Kit to develop therapies for critical mast and stem cell-mediated diseases. Building on niche-clearing technology from Stanford, Dr. Shizuru initiated a clinical program funded by the California Institute for Regenerative Medicine (CIRM) with $23M in grant support to safely condition patients prior to hematopoietic stem cell transplantation.

Jasper started out with a transplant conditioning focus, but has since expanded scope to treat mast cell disorders, hematopoietic stem cell disorders, and oncology. Jasper unites technologies from Stanford University and Amgen with cutting-edge science and expertise in mast cell biology, stem cell biology, HSC transplant, oncology and drug development. Jasper has acquired worldwide rights to Briquilimab (Formerly JSP191) from Amgen, which originally discovered JSP191 (formerly AMG191), as well as translational science and materials from Stanford University.